
|Articles|September 1, 2003
Patient compliance improves with twice-daily dosing
Fort Lauderdale, FL-A twice-daily dosing regimen of pemirolast potassium 0.1% ophthalmic solution (Alamast, Santen Inc., of Napa, CA, and Tampere, Finland) is as effective as the four-times-daily regimen of the drug for treating seasonal allergic conjunctivitis. The simpler dosing regimen may enhance patient compliance.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
3
Study maps thermal dynamics of glaucoma laser treatments
4
Alcon raises offer in amended deal to acquire STAAR Surgical
5














































.png)


